Logo
x

Search

Subscribe Now

Rocket Pharmaceuticals

Rocket Pharmaceuticals Reports the EMA’s Acceptance of MAA for RP-L102 to Treat Fanconi Anemia

Rocket Pharmaceuticals Reports the EMA’s Acceptance of MAA for RP-L102 to Treat Fanconi Anemia

  • April 2, 2024
Rocket Pharmaceuticals Receives the US FDA’s RMAT Designation of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals Receives the US FDA’s RMAT Designation of RP-A501 for the Treatment of Danon Disease

  • February 8, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.